![PDF) Comparative Bioavailability of 2 Tablet Formulations of Levodopa/ Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study PDF) Comparative Bioavailability of 2 Tablet Formulations of Levodopa/ Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study](https://i1.rgstatic.net/publication/51186451_Comparative_Bioavailability_of_2_Tablet_Formulations_of_LevodopaBenserazide_in_Healthy_Fasting_Volunteers_A_Single-Dose_Randomized-Sequence_Open-Label_Crossover_Study/links/5cec59f2458515026a612799/largepreview.png)
PDF) Comparative Bioavailability of 2 Tablet Formulations of Levodopa/ Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study
![Леводопа/Бенсеразид-Тева — инструкция по применению, дозы, побочные действия, отзывы о препарате Леводопа/Бенсеразид-Тева: таблетки, 200 мг+50 мг — Энциклопедия лекарств РЛС Леводопа/Бенсеразид-Тева — инструкция по применению, дозы, побочные действия, отзывы о препарате Леводопа/Бенсеразид-Тева: таблетки, 200 мг+50 мг — Энциклопедия лекарств РЛС](https://app.rlsnet.ru/api/storage/packing/gif/5297_a.gif)
Леводопа/Бенсеразид-Тева — инструкция по применению, дозы, побочные действия, отзывы о препарате Леводопа/Бенсеразид-Тева: таблетки, 200 мг+50 мг — Энциклопедия лекарств РЛС
![PDF) Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: A case series PDF) Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: A case series](https://i1.rgstatic.net/publication/38012326_Levodopacarbidopaentacapone_20050200_mg_StalevoR_200_in_the_treatment_of_Parkinson's_disease_A_case_series/links/545c259c0cf2f1dbcbcb0e68/largepreview.png)
PDF) Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson's disease: A case series
![Maladie de Parkinson : nouvel état des lieux sur la disponibilité de SINEMET, MODOPAR et génériques (Edit du 16 avril 2019) Maladie de Parkinson : nouvel état des lieux sur la disponibilité de SINEMET, MODOPAR et génériques (Edit du 16 avril 2019)](https://vidalactus.vidal.fr/files/uploads/actus/images/SINEMET_MODOPAR_LEVODOPA_CARBIDOPA_BENSERAZIDE_maladie_Parkinson_etat_lieux_approvisionnement_MSD_TEVA_Sante.jpg)
Maladie de Parkinson : nouvel état des lieux sur la disponibilité de SINEMET, MODOPAR et génériques (Edit du 16 avril 2019)
![PDF) Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar (R)/Prolopa (R) PDF) Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar (R)/Prolopa (R)](https://i1.rgstatic.net/publication/236337142_Pharmaceutical_quality_of_seven_generic_LevodopaBenserazide_products_compared_with_original_Madopar_RProlopa_R/links/0deec52b17df1c3564000000/largepreview.png)
PDF) Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar (R)/Prolopa (R)
Full article: Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease
![Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar) - Torti - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar) - Torti - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/adfc1227-14de-4d2a-8d75-e0c4fb371ce5/bcp.v85.11.cover.jpg?trick=1679367497089)
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar) - Torti - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library
![Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study | SpringerLink Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00702-009-0344-4/MediaObjects/702_2009_344_Fig1_HTML.gif)